Determining the best LDL cholesterol levels for small vessel occlusion stroke prevention

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)

Not applicable Interventional Seoul National University Hospital · NCT06649240

This study is testing the best cholesterol levels and treatments for people who have had small vessel occlusion strokes to see how they can prevent more strokes.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment4016 (estimated)
Ages19 Years and up
SexAll
SponsorSeoul National University Hospital Academic / other
Locations46 sites (Ansan and 45 other locations)
Trial IDNCT06649240 on ClinicalTrials.gov

What this trial studies

This study aims to establish optimal low-density lipoprotein (LDL) cholesterol targets specifically for patients who have experienced small vessel occlusion (SVO) strokes. It will compare the effects of intensive versus standard lipid-lowering therapies, including statins and other medications, on secondary prevention of ischemic strokes. By focusing on a specific subtype of stroke, the study seeks to fill a gap in current guidelines and improve patient outcomes through tailored cholesterol management. Participants will be recruited from multiple centers and will undergo rigorous screening to ensure eligibility based on defined criteria.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 19 years or older who have had a confirmed small vessel occlusive infarction within the last 180 days.

Not a fit: Patients requiring intensive LDL cholesterol management for other conditions or those contraindicated for statin use may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved secondary prevention strategies for patients with small vessel occlusion strokes, potentially reducing the risk of future strokes.

How similar studies have performed: While there have been studies on LDL cholesterol management in general, this specific focus on small vessel occlusion stroke is relatively novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 19 years or older
2. Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI or CT)
3. Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment
4. Patients or guardians who agree to the study protocol and sign with informed consent

Exclusion Criteria:

1. Patients requiring intensive LDL cholesterol management (LDL-C \<70 mg/dL) due to another condition, with LDL cholesterol targets specified in the guidelines for that condition
2. Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit, muscle disorders, hypersensitivity to statins, or taking medications contraindicated for use with statins)
3. Women who are pregnant, breastfeeding, or intending to become pregnant during the study period
4. Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion

Where this trial is running

Ansan and 45 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Ischemic StrokeSmall Vessel Cerebrovascular DiseaseCholesterol, LDLSecondary PreventionCardiovascular DiseasesCerebral Small Vessel DiseasesStatins
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.